AlphaQuest LLC Has $52,000 Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

AlphaQuest LLC raised its stake in Exact Sciences Co. (NASDAQ:EXAS) by 22,825.0% in the 4th quarter, HoldingsChannel reports. The fund owned 917 shares of the medical research company’s stock after buying an additional 913 shares during the quarter. AlphaQuest LLC’s holdings in Exact Sciences were worth $52,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXAS. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences in the 3rd quarter valued at about $34,000. Asset Planning Inc acquired a new stake in Exact Sciences in the 4th quarter valued at about $40,000. Modus Advisors LLC acquired a new stake in Exact Sciences in the 4th quarter valued at about $43,000. SBI Securities Co. Ltd. acquired a new stake in Exact Sciences in the 4th quarter valued at about $66,000. Finally, Kieckhefer Group LLC acquired a new stake in Exact Sciences in the 4th quarter valued at about $188,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Shares of EXAS opened at $44.28 on Friday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The firm’s 50 day moving average price is $50.77 and its two-hundred day moving average price is $58.39. The firm has a market cap of $8.23 billion, a P/E ratio of -7.95 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. On average, analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EXAS. Scotiabank raised their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Monday, February 24th. Royal Bank of Canada began coverage on shares of Exact Sciences in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 target price on the stock. BTIG Research raised their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. TD Cowen raised their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Barclays reduced their target price on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Two analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $70.83.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.